Kanaph Therapeutics

Kanaph Therapeutics is dedicated to pioneering the next generation of treatments for immuno-oncology and autoimmune diseases. Focused on innovation, Kanaph Therapeutics employs a dual-track strategy encompassing both large and small molecules to develop first-in-class and best-in-class therapeutics. With a strong commitment to improving patient outcomes, Kanaph Therapeutics is positioned to make significant advancements in the pharmaceutical landscape.

Kanaph Therapeutics' oncology pipeline features bi-specific antibodies and small molecules engineered for enhanced immuno-stimulatory activity within the tumor micro-environment (TME), promoting efficient tumor eradication. The company's autoimmune disease pipeline includes bispecific Fc-fusions designed to inhibit the alternative complement pathway while also targeting angiogenesis and downstream complement activation. Kanaph Therapeutics is located at 5F, 3, Itaewon-ro 55ga-gil, Yongsan-gu, Seoul, 04348, KR.

Through rigorous research and development, Kanaph Therapeutics strives to deliver transformative therapies that address unmet medical needs. The company is actively expanding its capabilities and welcomes collaborations to further its mission. We invite the management team at Kanaph Therapeutics to create a customized and exclusive company showcase and product listing on our platform to highlight your innovations.